Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

2018 Set to be Strong for the Global Ultrasound Market
Feature | Ultrasound Imaging | April 18, 2018 | Simon Harris
After a year of mixed fortunes, the global ultrasound market is set for a strong year in 2018.
Philips Integrates Reacts Tele-Ultrasound Platform on Lumify Portable Systems

Image courtesy of Philips Healthcare

News | Ultrasound Imaging | March 30, 2018
Philips in partnership with Innovative Imaging Technologies (IIT) announced an industry-first integrated tele-...
Clarius Initiates $200,000 Medical School Award Program
News | Ultrasound Imaging | March 30, 2018
Clarius Mobile Health is introducing its Clarius Medical School Award Program. Under that program, Clarius will grant...
Canon Receives FDA Approval for Ultrasound Liver Analysis Suite
Technology | Ultrasound Imaging | March 28, 2018
Canon Medical Systems USA Inc. received U.S. Food and Drug Administration (FDA) approval for a robust suite of...
Samsung Unveils New RS85A Ultrasound System at AIUM 2018

The RS85A MV-Flow allows for visualization of slow-flow micro vascularized structures, which can be difficult to assess with conventional power Doppler ultrasound. Photo courtesy of Business Wire.

Technology | Ultrasound Imaging | March 26, 2018
Samsung NeuroLogica announced the Samsung RS85A ultrasound system has received U.S. Food and Drug Administration (FDA)...
Canon Aplio i600 Ultrasound System Receives FDA Clearance
Technology | Ultrasound Imaging | March 26, 2018
March 26, 2018 — Healthcare professionals seeking a cost-effective imaging solution without compromising image qualit
News | Ultrasound Imaging | March 21, 2018
Key processes in the body are controlled by the concentration of calcium in and around cells. A team from the Technical...
Siemens Healthineers Introduces Portable Cardiovascular-Dedicated Ultrasound at ACC.18
News | Cardiovascular Ultrasound | March 13, 2018
At the American College of Cardiology’s (ACC) 67th Annual Scientific Session and Expo, March 10-12 in Orlando, Fla.,...
Overlay Init